P2B001 is an investigational drug. Investigational means that the drug has not been approved by the regulatory authorities yet. The possible discomforts, side effects and risks related to P2B001 treatment may not all be known. Based on previous studies with P2B001 as well as with the currently used doses of it components, pramipexole and rasagiline, the most common side effects may have are drowsiness, nausea and sleepiness; Headache, fatigue, tremor and insomnia are also possible side effects that can be observed with P2B001.
Patients who may be interested in participating in clinical trials should speak with their physician to learn more about the potential risks and benefits.